New hope for hard-to-treat breast cancer: SKB264 takes on chemo in major trial
NCT ID NCT06279364
First seen Jan 30, 2026 · Last updated May 23, 2026 · Updated 23 times
Summary
This study tests a new drug called SKB264 against standard chemotherapy as the first treatment for people with advanced triple-negative breast cancer that cannot be removed by surgery. The trial includes 524 adults whose tumors do not have a certain protein (PD-L1) or who have already received immunotherapy for early-stage disease. The goal is to see if SKB264 helps people live longer or keeps the cancer from growing longer than current treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.